Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
July 2, 2024 3:04 PM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,001.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Approval of donanemab (branded Kisunla) is likely to expand revenue for both Lilly and Biogen/Eisai as two players are needed to grow infrastructure.... More
Morgan Stanley on Eli Lilly (LLY): 'we expect LLY shares to trade flat to slightly up'
July 2, 2024 2:41 PM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,023.00 price target on Eli Lilly (NYSE: LLY)
The analyst comments "The approval was in line with our expectations and we expect LLY shares to trade flat to slightly up as a result. For... More
